Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
Page No.# 1/19
GAHC010283562025
2026:GAU-AS:1959
THE GAUHATI HIGH COURT
(HIGH COURT OF ASSAM, NAGALAND, MIZORAM AND ARUNACHAL PRADESH)
Writ Petition [Civil] no. 7345/2025
M/s Protech Telelinks, represented by its authorised signatory
Bhupinder Pal Singh, having its registered office at SCO – 104,
Sector 17, HUDA Jagadhri, Yamuna Nagar – 135001, Haryana,
and its factory premises at Village – Mauza Ogli, Suketi Road,
Kala Amb, District – Sirmour, Himachal Pradesh – 173030.
………………Petitioner
-VERSUS-
1.
The State of Assam, represented by the Commissioner &
Secretary to the Government of Assam, Health & Family Welfare
Department, Dispur, Guwahati, PIN – 781006, Assam.
2.
Assam Medical Services Corporation Limited, represented by
the Managing Director, having its registered address at Central
Drug Ware House Campus, Patherquery, Narengi, Guwahati,
Assam, PIN – 781026.
3.
The Managing Director, Assam Medical Services Corporation
Limited having its registered address at Central Drug Ware House
Campus, Patherquery, Narengi, Guwahati, Assam, PIN – 781026.
4.
The General Manager, Procurement, QC, IT, Logistics, Assam
Medical Services Corporation Limited.
……………….Respondents
Page No.# 2/19
BEFORE
HON’BLE MR. JUSTICE MANISH CHOUDHURY
Advocates :
Petitioner
:
Mr. G.N. Sahewalla, Senior Advocate, Mr. M.
Sahewalla, Advocate
Respondents
:
Mr. D.P. Bora, Standing Counsel, Health & Family
Welfare Department
Date of hearings
:
Date of pronouncement of judgment
03.02.2026, 05.02.2026 & 12.02.2026
:
12.02.2026
Whether the pronouncement is of the
Operative part of the judgment ?
:
Whether the full judgment has been
Pronounced ?
:
Yes
JUDGMENT & ORDER
In this writ petition under Article 226 of the Constitution of India, assail is made to a Firm
Debarment Notice bearing e-File no. : 509791/20138 dated 15.11.2025 [Annexure-XXIII]
issued under the hand of the Managing Director, Assam Medical Services Corporation Limited
[AMSCL], that is, the respondent no. 3. The Firm Debarment Notice has been issued on the
ground of non-supply of thirteen nos. of drugs and seventeen nos. of Purchase Orders [POs]
where supplies were found below 90%. By the Firm Debarment Notice, the petitioner has
been blacklisted and debarred from participating in any tender for a period of 3 [three] years
from the date of issuance of the impugned Final Debarment Notice in terms of Clause no. 5,
Page No.# 3/19
Sub-Clause – H, Pt. no. [ii] & Pt. no. [iii] and Sub-Clause – M for default in supply of thirteen
nos. of essential drugs against seventeen nos. of Purchase Orders [POs] as per details
mentioned in Annexure-A to the Firm Debarment Notice.
2.
In order to understand the nature of challenge, the events leading to the issuance of
the Firm Debarment Notice would require an exposition : By a Notice Inviting Tender
[Framework Agreement] dated 09.02.2023, the AMSCL invited online tenders for
empanelment of manufacturers for supply of essential drugs to various health facilities under
the Department of Health & Family Welfare, Government of Assam by entering into a
Framework Agreement valid for three years.
3.
As per the Notice Inviting Tender [NIT] and the Bidding Document, the primary
objective of the AMSCL is to act as the central procurement agency for procurement of
essential drugs, surgical, consumables & equipment, etc. on behalf of all the directorates /
body / agency / mission under the Health & Family Welfare Department and the Medical
Education & Research Department of the Government of Assam. By the NIT, the AMSCL had
intended to establish a Framework Agreement with manufacturers and the process of
empanelment would be valid for a period of three years with option to further extend the
period for another one year.
4.
The petitioner is a company registered under the Companies Act, 1956 with its
registered office at Yamuna Nagar, Haryana and its factory at Mauza Ogli, District – Sirmour,
Himachal Pradesh. The petitioner company [hereinafter also referred to as ‘the petitioner’, at
places, for easy reference] is a pharmaceutical manufacturer and supplier. It has claimed
work experience in the field of supplying medicines and essential drugs to different
Government and non-Government agencies across the country.
5.
Finding itself eligible to submit bid as per the terms and conditions of the NIT dated
09.02.2023, the petitioner submitted its bid. Upon bid evaluation, the bid of the petitioner
Page No.# 4/19
was adjudged as a valid bid. On 28.07.2023, the office of the respondent no. 3 issued a
Letter of Intent [LoI] to 185 nos. of bidders informing them that they had been empaneled,
after the process of e-tendering, for entering into a Framework Agreement each with the
AMSCL for three years for supply of essential drugs as per specification given in details in the
annexures attached to the LoI. In the list of 185 empaneled vendors, the name of the
petitioner company figured at Serial no. 185.
6.
In the NIT, the terms and conditions for the Framework Agreement were set forth. The
relevant terms and conditions were also mentioned in the LoI. It was stated that for every
procurement process, the empaneled manufacturers would be asked to submit price of the
item and Purchase Orders [POs] would be generated on the L-1 rate. Purchase Orders [POs]
would be issued in the ratio : 60 : 25 : 25 to the L-1 : L-2 : L-3, subject to the condition that
L-2 and L-3 would match the L-1 rate. If L-2 or L-3 would not match the L-1 rate, then the
next lowest bidder would be offered to match the L-1 rate. However, if the value of purchase
was less than Rs. 5.00 lakh, then the entire quantity would be awarded to the L-1 bidder. In
case the Tender Inviting Authority / Procuring Authority would find that L-2 and L-3 would not
be able to supply, then the Tender Inviting Authority / Procuring Authority would allot the
quantity to the L-1 bidder. It was further mentioned that the Tender Inviting Authority /
Procuring Authority would be at liberty to terminate the contract without assigning any
reasons thereof either wholly or in part on thirty days’ notice. The supplier would not be
entitled for any compensation whatsoever in case of such termination.
7.
The process of arriving at Contract Rate in the post-empanelment stage was laid down.
On the aspects of delivery and inspection, it was laid down in the following manner :-
E. Delivery & Inspection
i. Delivery Schedule as mentioned shall remain firm throughout the contract period. Cross
Conditions such as “SUBJECT TO AVAILABILITY” “SUPPLIES WILL BE MADE AS AND
Page No.# 5/19
WHEN SUPPLIES ARE RECEIVED” etc., will not be considered under any circumstances
and the bids of those who have given such conditions shall be treated as incomplete and
Tender will be summarily rejected. Supplies should also be made directly by the bidder and
not through any other agency.
ii.
Point of Delivery: The ordered items shall be delivered at State Drug Ware House
based on Guwahati or different District Drug Stores / Medical College Stores located in
different districts of Assam in accordance to instructions in the order. All supplies will be
scheduled for the period from the date of purchase order till the completion of the supply or,
as would be stipulated in the Purchase Order. However, if the total value of the Purchase
Order [not the value of individual item included in PO] will be less than equal to Rs. 1.00
lakh, the consignment to be delivered centrally at Guwahati.
iii. Purchase Order will be placed on the successful Bidder at the discretion of the AMSCL.
If the Purchase Order quantity is less than 1,00,000 Tab / Cap, or less than 10,000
injections / bottles / tubes / tests in one supply order or PO [Purchase Order], the supplies
will be allowed in trade pack where both generic & brand name should be there. However,
the label should possess the required logogram & the price should not appear on the label.
iv. Delivery Period: Supply shall commence within best possible time from the date of
Order and supply of full quantity shall be completed within 60 days from the date of issuing
the order. In case supply is not started within contractual delivery period then Purchase
Order may be cancelled.
*
*
*
*
*
*
vi. E Way Bill : AMSCL will not take any responsibility for providing the E-Way Bill. It will be
the responsibility of supplier to arrange for Way Bill for dispatch of consignments to Assam.
8.
On receipt of the LoI, the petitioner submitted a duly filled and signed agreement along
Page No.# 6/19
with the necessary annexure to the Tendering Authority on 31.07.2023. A Framework
Agreement was entered into between the respondent no. 3 and the petitioner on 31.07.2023.
The detailed list of the drugs quoted by the petitioner company for supply was mentioned in
the annexures to the Framework Agreement. As per the Framework Agreement, the
petitioner company was to supply the requisite items [drugs] at the designated locations in
Assam as and when required and as per the instructions given in the Purchase Orders [POs]
issued from time to time.
9.
According to the petitioner, it was consistently executing the Purchase Orders [POs],
issued from time to time. The petitioner has projected that most of the drugs ordered
through the POs were satisfactorily supplied and delivered to the designated warehouses and
locations as per the instructions given therein.
10. However on 02.07.2024, the respondent no. 4 made a communication to the petitioner
in reference to six Purchase Orders [POs] issued between 02.02.2024 to 06.02.2024 to inform
that the petitioner did not complete the supplies within the contracted delivery period, that is,
75 days from placing the POs and due to such delayed delivery, it had attracted the highest
late delivery charges @ 2% of the value of delayed goods per week of delay or part thereof
subject to a maximum of 10% of the total value. The petitioner was given 10 days’ time to
complete the supply from 02.07.2024 or else, penalties would be levied upon the petitioner as
per Tender Clause no. 5, Sub-Clause – H, Pt. no. [i] ‘Product Debarment’; Pt. no. [ii] ‘Firm
Debarment’; Pt. no. [iii] ‘Forfeiture of Performance Security’; and Clause no. 5, Sub-Clause –
M, ‘Alternative Purchase’. Reference of the concerned Purchase Orders [POs] was made in
Annexure-A to the said Letter. In response, the petitioner vide its Letter dated 03.07.2024
made an assurance that they would be able to complete the delivery within a period of 20
days approximately at all specified locations and apologized for any inconvenience caused for
the delay.
11.
Subsequent Letters as regards default in supply of drugs on the part of the petitioner
Page No.# 7/19
were also issued to the petitioner from time to time mentioning that since the items [drugs]
ordered were essential in nature for needy patients in Government Hospitals of the State,
their non-supply had resulted in non-availability and hindrances and such late delivery / nondelivery would attract debarment / blacklisting. Such Letters were issued on and from
12.09.2024 onwards. In most of the occasions, the petitioner was found to have responded in
writing to request for additional time to complete the supply and not to proceed with any
action for debarment or blacklisting. The Procuring Authority had extended the time period of
supply on many occasions till 21.05.2025.
12.
While extending the time period for supply in terms of the Purchase Orders [POs]
beyond the stipulated delivery period, the Tendering Authority / Procuring Authority had also
issued Show Cause Notices in the interregnum. The first Show Cause Notice bearing no.
509791/87773 was issued on 06.01.2025 followed by a second Show Cause Notice bearing
no. 509791/115735 on 07.03.2025. A Final Show Cause Notice for default in supply was
issued on 21.05.2025. By referring to the delivery status in the DVDMS Portal, as on that date
and as per Annexure-A thereto, the Tendering Authority / Procuring Authority by the Final
Show Cause Notice asked the petitioner to show cause as to why its products should not be
debarred as per the penal clauses of the Tender, namely, Clause 5 : ‘Terms & Conditions’,
Sub-Clause – H : ‘Debarment / Blacklisting’ for failure in execution of supply / non-supply /
default in supply. The petitioner was asked to submit its reply within three days indicating
that in the event of non-submission of reply, administrative as well as financial penalties
would be levied. In response, the petitioner sent a mail on 11.06.2025 expressing regret for
the inconvenience caused and seeking certain clarifications regarding validity of the Purchase
Orders [POs]. On 01.07.2025, while giving extension of seven days to complete the supply of
entire items mentioned in Annexure-A thereto, citing greater public interest, the Tendering
Authority / Procuring Authority reiterated its proposed action in terms of Clause 5. In
Annexure-A, reference of 39 Purchase Orders [POs] were made indicating the details of
percentage of delivery made till 27.06.2025 against each PO. Extension for further ten days
was made on 12.08.2025.
Page No.# 8/19
13.
Another Show Cause Notice terming it as a Final Show Cause Notice was issued to the
petitioner on 09.09.2025 proposing to take action, as indicated in the earlier Show Cause
Notices, in terms of Clause 5 of the Terms and Conditions. Another extension of seven days
to complete the supplies was given on 26.09.2025. On 07.10.2025, the petitioner made a
request for extension of delivery period for another fifteen days. Again on 04.11.2025,
another notice terming it as Final Notice was issued to the petitioner while granting seven
days as last opportunity to complete the pending supply failing which there would be
debarment of products / company.
14.
It was in the backdrop of the afore-stated facts and circumstances, the impugned Firm
Debarment Notice for non-supply of required quantity of ordered essential drugs came to be
issued in reference to the earlier Show Cause Notices including the Final Notice -cumExtension issued on 04.11.2025. It was mentioned that all efforts through the previous
notices, show causes, extensions, official communications were made to get the supplies from
the petitioner and enough opportunities were given to the petitioner to execute the supplies
of essential drugs in terms of the POs in a time-bound manner. Yet, the petitioner had
defaulted creating non-availability of essential drugs resulting in increase in expenditure. It
was indicated that as per the DVDMS Portal, as on that date, there was total non-supply of
thirteen nos. of essential drugs against seventeen nos. of Purchase Orders [POs]. Supplies
were found below 80% in respect of eleven Purchase Orders [POs]. In case of six Purchase
Orders [POs], supplies were found above 80% but below 90%. Supply in respect of one
Purchase Order [PO] was not even started. Reiterating that the tender norms required supply
of a minimum of 90% within the stipulated delivery period, the impugned Final Notice
mentioned that in the greater public and patient interest, the petitioner company had been
blacklisted and debarred from participating in any tender for three years from the said date
as per Clause no. 5, Sub-Clause – H, Pt. no. [ii] & Pt. no. [iii] and Sub-Clause – M for default
in supply of thirteen nos. of essential drugs against seventeen nos. of Purchase Order [POs],
as per details mentioned in Annexure-A to the Firm Debarment Notice.
15.
I have heard Mr. G.N. Sahewalla, learned Senior Counsel assisted by Mr. M. Sahewalla,
Page No.# 9/19
learned counsel for the petitioner and Mr. D.P. Bora, learned Standing Counsel, Health &
Family Welfare Department for all the respondents.
16.
Mr. Sahewalla, learned Senior Counsel appearing for the petitioner has highlighted the
various terms and conditions incorporated in the Bidding Document and the Framework
Agreement. Specifically referring to Clause 5, Sub-Clause – H, he has contended that the
petitioner company has been shortlisted for a nos. of items [drugs]. From time to time,
Purchase Orders [POs] were issued with a stipulated delivery period of 75 days. Each
Purchase Order [PO] pertained to one item [drugs] with delivery destinations. As per SubClause [i] of Clause 5H, it is only in case of non-supply or incomplete supply i.e. less than
90% of the total ordered quantity for a particular item [drugs] within the agreed delivery
period including the delayed penalty period or any extended delivery period, the Procuring
Authority can resort to the action of cancellation of the Rate Contract at first and the
empaneled vendor can be debarred from participating in any bidding process called by the
Procuring Authority for a period of five years from the date of debarment for that particular
item [drugs] only. It is only in the event an empaneled vendor is debarred for all the items
where it has Rate Contract for less than three items or at least three items where it holds
Rate Contract more than equal to three items, the action of blacklisting and debarment can
be contemplated. The Procuring Authority cannot resort to the penalty of Firm Debarment
without resorting to Product Debarment, that too, for at least three items [drugs] at first. On
the factual front, he has contended that if all the Purchase Orders [POs] in respect of each of
the items [drugs] are calculated, it would be evident that the petitioner company had
delivered at least 90% in respect of all the items [drugs]. Therefore, there could not have
been cancellation of any Rate Contract and resultantly, Product Debarment. As no such
situation had arisen, the action taken in the form of Firm Debarment is clearly arbitrary and
high handed and therefore, the impugned Firm Debarment Notice is liable to be set aside and
the petitioner company shall be allowed to proceed for delivery of any remaining quantity of
items [drugs], if any. He has further submitted that the issue arisen in this case is covered by
a judgment of a Bench of co-ordinate jurisdiction rendered in W.P.[C] no. 6735/2025 [Nestor
Pharmaceutical Limited and another vs. the State of Assam and five others].
Page No.# 10/19
17.
Per contra, Mr. Bora, learned Standing Counsel, Health & Family Welfare Department
representing the respondents has submitted that it would be evident from the Show Cause
Notices, notices with regard to default in supply, extension notices, etc. issued to the
petitioner company from time to time with regard to the Purchase Orders [POs] referred
therein that there had been consistent failures on the part of the petitioner company in
delivering the ordered items [drugs] at the destinations within the stipulated delivery periods
and even, within the extended delivery periods. It was in such extreme compelling situations,
there was no option left to the respondent authorities but to take the action of Firm
Debarment against the petitioner. It is the public interest which is behind the action taken. He
has submitted that the ordered items [drugs] are meant for needy patients admitted in
various health facilities across the State and any case of non-supply or incomplete supply has
serious consequences. He has contended that the case of the petitioner in Nestor
Pharmaceutical Limited [supra] cannot be readily made applicable to the case of the
petitioner herein without examining and comparing the facts and circumstances of the two
cases at first. It is his contention that the action taken against the petitioner is as per the
terms and conditions of the Bidding Document and the Framework Agreement and therefore,
no interference is called for in respect of the Firm Debarment Notice dated 15.11.2025.
18. I have considered the submissions advanced by the learned counsel for the parties and
have also gone through the materials on record.
19. As the actions taken through the impugned Firm Debarment Notice are based on various
sub-clauses under Clause 5H of the terms and conditions of the Bidding Document, it is
appropriate to refer to them at first. Clause 5G is with regard to ‘Delivery, Shortage & Delay
Penalty’. The various relevant sub-clauses of Clause 5G and Clause 5H are as under :-
G.
Delivery, Shortage & Delay Penalty
Page No.# 11/19
i.
In case there is delay in delivery beyond the stipulated period as mentioned in
the purchase order, there shall be penal deduction @ 2.0% of the value of delayed
goods per week of delay or part thereof subject to a maximum of 10% of the total
order value. Once the maximum price reduction is reached, termination of the
Purchase Order will be considered.
ii.
In case alternate purchase is made, the incremental / additional cost, if any
incurred for such purchase shall be recovered from the defaulter.
H.
Debarment / Blacklisting for failure in execution of supply / non-supply /
default in supply.
i.
Product Debarment : In case of non-supply or incomplete supply [i.e. less
than 90% of the total ordered quantity] by the approved manufacturer / importer
[Firm] within agreed delivery period including the delay penalty period or any such
extended delivery period then the concerned rate contract cancelled and
manufacturer / importer [Firm] shall be debarred for participating in any bid called
by the Authority for 5 years from the date of debarment for that item. In case the
manufacturer / importer [Firm] supply 90% or more of the ordered quantity but fails
to supply the entire quantity within the allowed delivery period then the firm shall be
levied a penalty @ 10% of the value of the short supplied item and same shall be
adjusted against the payment for supply.
ii.
Firm Debarment : The firm shall be blacklisted and debarred from
participating in any tender by the TIA or procuring agency for 3 [three] years if the
company is debarred for all the items [where it has RC-‘Rate Contract’ for less than
3 items] or at least 3 items [where it holds RC-‘Rate Contract’ for more than equal
to 3 items].
iii.
Forfeiture of Performance Security :
Page No.# 12/19
[a]
In case of Product Debarment : In addition to product debarment the
performance security deposited by the supplier for that particular product shall
be forfeited and apportioned towards financial penalty.
[b]
In case of Firm Debarment : In addition to firm debarment entire
performance security deposited by the supplier shall be forfeited and
apportioned towards financial penalty.
iv.
The order stands cancelled after the expiration of delivery period, and if the
extension is not granted with or without liquidated damages. Apart from risk /
alternate purchase action, the Bidder shall also suffer forfeiture of the performance
security and shall invite other penal action like blacklisting / debarring
disqualification from participating in present and future Bids of Bid Inviting
Authority / Ordering Authority.
v.
If the supplier, or any of its approved items gets debarred / banned /
blacklisted in any state after entering into agreement with AMSCL it shall be the
responsibility of the supplier to inform AMSCL without any delay about the same.
vi.
The Successful Bidder shall not, at any time, assign, sub-let or hand over the
contract or the benefit thereof or any part thereof to any person or persons
whatsoever.
vii.
It shall be the responsibility of the supplier for any shortages / damage at the
time of receipt in warehouse. AMSCL is not responsible for the items supplier at the
point of delivery, for which no order is placed.
20. Annexure-B of the Framework Agreement [Contract Agreement] listed 67 nos. of drugs
quoted by the petitioner company. The Framework Agreement has mentioned that the
petitioner company as the supplier had agreed to supply to the Procuring Authority the items
Page No.# 13/19
with specifications mentioned in the Schedule attached. The petitioner company as the
supplier shall make supplies of the items on the basis of Purchase Orders [POs] placed on it
from time to time by the Ordering Authorities specifying the quantities required to be supplied
at the specified locations in the State of Assam.
21.
From the materials brought on record by the petitioner company including the notices
for default issued to it by the Procuring Authority, it reveals that more than fifty Purchase
Orders [POs] were issued to the petitioner company during July – October, 2025. During the
year 2024, more than thirty-five Purchase Orders were issued to the petitioner company for
delivery. It was in the Extension Notice to complete the supply issued on 21.04.2025, mention
was made of maximum thirty-eight nos. of Purchase Orders [POs] issued between the period
from 02.02.2024 to 05.12.2024 stating that in respect of those Purchase Orders [POs]
delivery were not made within the stipulated delivery period of 75 days mentioned in the
Purchase Orders [POs]. It was mentioned that except eleven Purchase Orders [POs],
percentage of delivery did not reach 90%. The thirty-eight Purchase Orders [POs] include
more than one Purchase Orders [POs] for the same drug. For example, there were three
Purchase Orders [POs] for ‘Dopamine Injection 40 mg/ml’ for different quantities. There were
four Purchase Orders [POs] for ‘Carboprost Trometahmine Injection mg/ml’ for different
quantities on different dates. For the drug, ‘Piperacillin [A] Plus Tazobactam [B] Powder for
Injection 4 g [A] Plus 500 mg [B]’, there were six different Purchase Orders [POs] on different
dates for different quantities. The Statement annexed to the Extension Notice dated
21.04.2025 showed different dates of delivery against different Purchase Orders [POs].
Similarly, the statement attached to the Extension Notice dated 01.07.2025mentioned about
thirty-nine Purchase Orders [POs] issued during the period from 17.04.2024 to 14.05.2025 for
different drugs with a number of Purchase Orders [POs] for the same drug. The statement
projected a similar scenario as like the Extension Notice dated 21.04.2025.
22. In the Firm Debarment Notice dated 15.11.2025, the respondent authorities to support
its case have referred to delivery status of in respect of seventeen Purchase Orders [POs], as
on 14.11.2025, uploaded in the Drug and Vaccine Distribution Management System. The
Page No.# 14/19
Drugs and Vaccine Distribution Management System [DVDMS] is an IT-based application used
for managing the supply chain of drugs and vaccines. The contention of the respondents is
controverted by the petitioner by stating that the Purchase Orders [POs] issued for each drug
including the thirteen drugs enumerated in the impugned Firm Debarment Notice were as per
the Rate Contract which had resulted pursuant to submission of the bid by the petitioner. It is
contended that the supply was required to be made in terms with the firm rate arrived at. It
is further contended that all the Purchase Orders [POs] against each Rate Contract for each
drugs had to be taken together for ascertaining the total amount / percentage of supply
made by the petitioner. The petitioner has taken a stand that Clause 5, Sub-Clause – H, Pt.
no. [i] of the Bidding Document do not refer to Purchase Orders [POs] but refers to the total
ordered quantity and it is only non-supply of 90% of the total ordered quantity would lead to
Product Debarment. The petitioner has sought assert that in its case, if the cumulative supply
of all the thirteen drugs as mentioned in the impugned Firm Debarment Notice dated
15.11.2025 is taken together on per drug basis, then the petitioner has a supply percentage
of more than 95% for all the drugs except one i.e. Vecuromium Powder for Injection 4 mg,
where the petitioner had supplied only to the extent of 67.34% as a whole. In support of its
such contention, the petitioner has annexed a statement showing cumulative percentage of
the debarred items of the petitioner. On perusal of the statement showing cumulative
percentage of the debarred items, it is noticed that the petitioner has projected that it had
achieved more than 90% delivery status in respect of thirteen items [drugs] as against the
Purchase Orders [POs] issued in its favour from time to time. The claim of the respondents as
regards delivery of lesser than 90% and the counterclaim of the petitioner as regards delivery
of more than 90% in respect of the concerned thirteen items [drugs] are matter of factual
determination. Irrespective of it, the issue of debarment is to be examined also in the context
of the procedure followed for debarment of the company.
23.
An order of debarment / blacklisting has the effect of preventing a person or an entity
from the privilege and advantage of entering into lawful relationship with the State or an
instrumentality / agency of the State. It is well settled that in the context of debarment /
blacklisting of a person or an entity by the State or an instrumentality / agency of the State,
Page No.# 15/19
the requirement of a valid, particularized and unambiguous show cause notice is crucial due
to the serious consequences of debarment / blacklisting and the stigmatization that accrues
to the person / entity being debarred / blacklisted. Debarment / blacklisting visits the persons
/ entity with long lasting civil consequences for the further business prospects of the debarred
/ blacklisted person / entity.
24.
The matters of Rate Contract and Parallel Rate Contracts involved in the empanelment
process initiated by the NIT dated 09.02.2023 and envisaged by the terms and conditions in
the Framework Agreement came up for consideration before a co-ordinate Bench in a writ
petition, W.P.[C] no. 6735/2025 [Nestor Pharmaceuticals Limited and another vs. the State of
Assam and five others], decided on 11.12.2025. In the said case, the interpretation with
regard to Rate Contract and Parallel Rate Contract have been in deference to the provisions of
the Assam Public Procurement Act, 2017, an Act enacted by the Assam State Legislative
Assembly, and the Assam Public Procurement Rules, 2020 framed thereunder as the
provisions therein are found applicable to the type of procurement carried out by the
respondent authorities herein.
25. Analyzing the terms and conditions contained in Clause 5H[i] of the Bidding Document,
it has been observed that upon issuance of a Purchase Order [PO] to the L-1 bidder or any
other bidder who agrees to supply at the L-1 rate and if there is a failure to supply or there is
an incomplete supply to the extent of less than 90% of the total ordered quantity, the Rate
Contract for the essential drug would be cancelled and upon such cancellation, the
manufacturer / importer firm shall be debarred from participating in any bid called by the
authority for five years from the date of debarment for that essential drug / item. The
cancellation of the Rate Contract would be qua the L-1 bidder or the Parallel Rate Contract
qua the bidders who matches the L-1 rate. It has been observed that in a circumstance where
there is no Parallel Rate Contract but only one Rate Contract and the said Rate Contract being
cancelled, it would lead to a fresh procurement process for the purpose of ascertaining the
lowest price for the item in question. It is under such circumstances, Clause 5H[i] of the
Bidding Document imposes a penalty of Product Debarment in respect to the item for a
Page No.# 16/19
period of five years. Such penalty is in a form of deterrent so that the supplier does not fail to
supply or supplies less than 90% of the total ordered quantity.
26.
The Court has, interpreting the sub-clause [i] and sub-clause [ii] of Clause 5H of the
Bidding Document, has proceeded to hold as under :-
40.
Clause 5H[ii] of the Bidding Document pertains to ‘Firm Debarment’ i.e. the
manufacturer or the importer with whom a rate contract has been entered into for less
than three items when debarred for all the items or when the manufacturer / supplier
is debarred at least for three items where it holds rate contract for more than or equal
to three items. It is to be kept in mind that Firm Debarment is a more punitive action
than a Product Debarment inasmuch as upon Product Debarment, only one item is
debarred whereas in the case of Firm Debarment, the manufacturer as a whole is
debarred irrespective of how many items it had a Rate Contract.
41. This Court finds it pertinent to observe that the recourse to Firm Debarment can
only take place when a manufacturer is debarred for all items where it has a rate
contract for less than three items and a manufacturer would be debarred when the
manufacturer has a rate contract of more or equal to three items and three items
have been debarred. It is apposite to observe that the items first have to be debarred
by cancellation of the rate contract or in other words, Product Debarment precedes
Firm Debarment.
42.
It is therefore the opinion of this Court that without there being a Product
Debarment upon cancellation of the Rate Contract for the item, the question of going
into Firm Debarment is not envisaged on a conjoint reading of Clause 5H[i] and
Clause 5H[ii] of the Bidding document.
27. In so far as the facts involved in the case of Nestor Pharmaceutical Limited [supra] are
Page No.# 17/19
concerned, the respondent authorities had resorted to taking action for Firm Debarment in
terms of Clause 5H[ii] of the Bidding Document without carrying out Product Debarment in
respect of the four essential drugs of the petitioner company therein by cancellation of the
Rate Contracts against each of the four items. By a Debarment Notice dated 17.11.2025, the
respondent authorities had blacklisted and debarred the petitioner company therein from
participating in any tender for three years from the date of issuance of the Debarment Notice
in terms with Clause 5, Sub-Clause – H, Pt. no. [ii] and Pt. no. [iii] and Sub-Clause – M for
default in supply of four nos. of essential drugs against four nos. of Purchase Orders [POs].
The Court has further recorded that the respondent authorities had on the basis of nonsupply of 90% of the ordered quantity in respect to one Purchase Order [PO] against each
four essential drugs arrived at an opinion that the petitioner company therein had failed to
supply 90%. The Court has observed that Clause 5[i] of the Bidding Document did not refer
to Procurement / Purchase Order but referred to the total ordered quantity and non-supply of
90% of the total ordered quantity would lead to Product Debarment. The consolidated table
prepared by the petitioner company there had revealed that though the petitioner company
did not complete 90% in respect to one Purchase Order [PO] against each of the four items
but the overall supply it had made against the total ordered quantity against each four items
was much more than 90%. Observing so, the Court has observed that the question of
cancellation of the Rate Contract or Product Debarment in terms of Clause 5H[i] of the
Bidding Document did not arise and at the most, the respondent authorities could have
resorted to Clause 5G[i] of the Bidding Document to levy the penalty of 10% of the value of
the short-supply by adjusting the same against the payment for the supply or could have
made alternate purchase. The Court has further held that in no case, the question of Product
Debarment or Firm Debarment had arisen in the facts and circumstances of the case.
28. Reverting back to the facts of the case in hand, the Show Cause Notices and the Notices
for default in supply and extension of time, as mentioned above, were found to have
emphasized on the different Purchase Orders [POs], not specifically on the ordered items
[drugs] therein. In a same Notice, more than one Purchase Orders [POs] were referred to
and accordingly, percentage of supply were mentioned against each individual Purchase
Page No.# 18/19
Order [PO]. There were no mention of non-supply or incomplete supply on the basis of total
ordered quantity of each items [drugs]. Moreover, different Notices made mention of different
Purchase Orders [POs] of different periods. Resultantly, no consistency is found in the Notices
when considered in seriatim beginning from 02.07.2024 to the Firm Debarment Notice issued
finally on 15.11.2025. In such obtaining fact situation, the Notices were found lacking specific
particulars vis-à-vis the provision contained in Clause 5, Sub-Clause – H, Pt. no. [i]. The
impugned Firm Debarment Notice dated 15.11.2025 was not issued for the purpose of
Product Debarment as per Clause 5, Sub-Clause – H, Pt. no. [i].
29. The law is well settled that a decision rendered by a co-ordinate Bench is binding on the
subsequent Benches of equal or lesser strength. The law is settled that a decision of a Bench
of co-ordinate jurisdiction is to be followed and respected by another Bench of similar
jurisdiction. Judicial discipline envisages that a co-ordinate Bench should follow the decision
of an earlier co-ordinate Bench and no decision is to be arrived at contrary to or inconsistent
with the law laid down by the co-ordinate Bench. It is admitted at the Bar that there is no
appeal pending, as on date, against the Judgment delivered in W.P.[C] no. 6735/2025. In
such situation, a co-ordinate Bench has to proceed to decide matters on the basis of the law
as it stands, as the Judgment and Order rendered in the case of Nestor Pharmaceutical
Limited [supra] has vested, as on date, attaining a status of finality.
30.
When the basis of challenge made to the Firm Debarment Notice issued in the case of
Nestor Pharmaceuticals [supra] and the basis of interference are compared with the
impugned Firm Debarment Notice involved in the present case and the basis on which
interference has been sought for, this Court is of the considered view that there is similarity in
the two cases. The issue is settled that as per the terms and conditions of the Bidding
Document and the Framework Agreement that there cannot be Firm Debarment without
being preceded a Product Debarment upon cancellation of the Rate Contractsor Parallel
Contracts for at least for three items [drugs]. In the case in hand, the respondent authorities
have resorted to take action for Firm Debarment in terms of Clause 5, Sub-Clause – H, Pt. no.
[ii] of the Bidding Document without carrying out Product Debarment for at least three
Page No.# 19/19
essential items [drugs] by cancellation of the Rate Contracts or Parallel Rate Contracts against
at least those three essential drugs.
31. In view of the facts involved in the case, as noted above, and the circumstances leading
to the impugned action of Firm Debarment qua the clauses in the Bidding Document, the
action of the respondent authorities in issuing the Firm Debarment Notice dated 15.11.2025
without being preceded by any action of Product Debarment / Rate Contract is to be held as
arbitrary and not sustainable. Accordingly, the impugned Firm Debarment Notice is set aside
and quashed. As a result, all other subsequent and consequential actions taken on the basis
of the Firm Debarment Notice dated 15.11.2025 are also termed as invalid.
32.
Clause 5, Sub-Clause – G has prescribed for penal deduction and termination of
Purchase Order. It is made clear that this Court has not made any observation as regards any
delivery beyond stipulated period as mentioned in any Purchase Order [PO] and any penalty
imposed, if any, on the ground of delayed delivery of items [drugs] earlier to the impugned
Firm Debarment Notice.
33. With the observations made and findings reached above, the writ petition is allowed to
the extent indicated above. There shall, however, be no order as to cost.
JUDGE
Comparing Assistant
Basumatary
Date: 2026.02.12 15:19:31
+05'30'
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review